Founded in 2002, China Biologic Products Holdings, Inc. (NASDAQ: CBPO), is a leading fully integrated plasma-based bio-pharmaceutical company in China. China Biologic’s core capabilities include plasma collection, and the manufacturing and commercialization of human plasma-based bio-pharmaceutical products. These products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. Headquartered in Beijing, the company manufactures products through their facilities in Guizhou Province, Shandong Province, and Shaanxi Province.